Throughout life, bone tissue undergoes a continuous process of resorption and formation. Melatonin, with its antioxidant properties and its ability to detoxify free radicals, as suggested by Conconi et al. (2000) may interfere in the osteoclast function and thereby inhibit bone resorption, as suggested by Schroeder et al. (1981). Inhibition of bone resorption may be enhanced by a reaction of indoleamine in osteoclastogenesis. That it has been observed melatonin, at pharmacological doses, decrease bone mass resorption by suppressing through down regulation of the RANK-L, as suggested by Penarrocha Diago et al. (2005) and Steflik et al. (1994). These data point an osteogenic effect towards that may be of melatonin of clinical importance, as it could be used as a therapeutic agent in situations in which would be advantageous bone formation, such as in the treatment of fractures or osteoporosis or their use as, a bioactive surface on implant as suggested by Lissoni et al. (1991).
展开▼
机译：在整个生命过程中，骨组织经历了连续的吸收和形成过程。如Conconi等人所建议的那样，褪黑素具有抗氧化特性和对自由基的解毒能力。 Schroeder et al。（2000）可能会干扰破骨细胞的功能，从而抑制骨吸收。 （1981）。吲哚胺在破骨细胞形成中的反应可以增强对骨吸收的抑制作用。如Penarrocha Diago等人所建议的，已经观察到褪黑激素在药理学剂量下通过抑制RANK-L的表达来抑制骨质吸收。 （2005）和Steflik等。 （1994）。这些数据表明对骨形成的影响可能具有褪黑激素的临床意义，因为它可以在有利的骨形成的情况下用作治疗剂，例如在骨折或骨质疏松症的治疗或将其用作治疗根据Lissoni等人的建议，植入物具有生物活性。 （1991）。
展开▼
